Share on StockTwits
 

Investment analysts at Barclays raised their price target on shares of Actavis (NYSE:ACT) from $190.00 to $230.00 in a note issued to investors on Monday, AnalystRatings.NET reports. The firm currently has an “overweight” rating on the stock. Barclays’ target price suggests a potential upside of 26.33% from the company’s current price.

A number of other analysts have also recently weighed in on ACT. Analysts at JPMorgan Chase & Co. raised their price target on shares of Actavis from $215.00 to $230.00 in a research note to investors on Monday. Separately, analysts at Piper Jaffray raised their price target on shares of Actavis from $175.00 to $203.00 in a research note to investors on Tuesday, January 28th. They now have an “overweight” rating on the stock. Finally, analysts at Argus raised their price target on shares of Actavis from $180.00 to $198.00 in a research note to investors on Friday, January 17th. They now have a “buy” rating on the stock. Six analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. Actavis currently has an average rating of “Buy” and an average price target of $175.16.

Actavis (NYSE:ACT) traded down 3.66% on Monday, hitting $182.07. 2,203,931 shares of the company’s stock traded hands. Actavis has a 52-week low of $82.02 and a 52-week high of $191.17. The stock has a 50-day moving average of $174.1 and a 200-day moving average of $151.4. The company’s market cap is $31.680 billion.

Actavis, Inc formerly Watson Pharmaceuticals, Inc, is a integrated global specialty pharmaceutical company engaged in the development, manufacturing, marketing, sale and distribution of generic, branded generic, brand, biosimilar and over-the-counter (NYSE:ACT) pharmaceutical products.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.